Teladoc Health, Inc. (NYSE:TDOC) Q3 2022 Earnings Conference Call October 26, 2022 4:30 PM ET

Company Participants

Patrick Feeley - VP, IR

Jason Gorevic - CEO & Director

Mala Murthy - CFO

Conference Call Participants

Lisa Gill - JPMorgan Chase & Co

Richard Close - Canaccord Genuity

Jailendra Singh - Truist Securities

Daniel Grosslight - Citigroup

Cindy Motz - Goldman Sachs

Jessica Tassan - Piper Sandler & Co.

Charles Rhyee - Cowen and Company

Sameer Patel - Evercore

Sean Dodge - RBC Capital Markets

Ryan Daniels - William Blair & Company

Stephanie Davis - SVB Securities

George Hill - Deutsche Bank

Operator

Hello and welcome to the Teladoc Health Third Quarter 2022 Earnings Conference Call. My name is Alex, and I'll be coordinating the call today. [Operator Instructions].

I'll hand over to your host, Patrick Feeley, Head of Investor Relations. Patrick, please go ahead.

Patrick Feeley

Thank you and good afternoon. Today, after the market closed, we issued a press release announcing our third quarter 2022 financial results. This press release and the accompanying slide presentation are available on the Investor Relations section of the teladochealth.com website. On this call to discuss the results are Jason Gorevic, Chief Executive Officer; and Mala Murthy, Chief Financial Officer. During this call, we will also provide our fourth quarter and full year 2022 outlook, and our prepared remarks will be followed by a question-and-answer session.

Please note that we'll be discussing certain non-GAAP financial measures that we believe are important in evaluating Teladoc Health's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release that is posted on our website.

Also, please note that certain statements made during this call will be forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause the actual results for Teladoc Health to differ materially from those expressed or implied on this call. For additional information, please refer to our cautionary statement in our press release and our filings with the SEC, all of which are available on our website.

I would now like to turn the call over to Jason.

Jason Gorevic

Thank you, Patrick. Good afternoon and thanks for joining us. After the close today, Teladoc Health reported strong third quarter results driven by solid execution across the business. Revenue grew 17% over the prior year to $611 million, above the midpoint of our guidance range. And adjusted EBITDA of $51 million exceeded the high end of our expectations.